Αρχική World News Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and Metastatic...

Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer

Safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent irrespective of age. Furthermore, patients aged ≥65 years can derive long-term progression-free survival (PFS) benefit and durable tumour response from the maintenance treatment according to an additional analysis of the POLO trial. Study investigators led by Dr. Hedy Lee Kindler of the University of Chicago in Chicago, US presented the findings at ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July).

The authors explained that in the phase III POLO study, treatment with maintenance olaparib provided a statistically significant and clinically meaningful improvement in PFS in comparison to placebo among patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy.

While a subgroup analysis showed consistency of treatment effect across prespecified groups, the hazard ratio in patients aged ≥65 years was 1.02 (95% confidence interval [CI] 0.45-2.60) according to 2019 publication by Golan et al. in The New England Journal of Medicine. To better determine the efficacy and safety of olaparib in patients aged ≥65 years, the study team performed additional analyses by age group.

Following at least 16 weeks of treatment with first-line platinum-based chemotherapy, patients without progression were randomised to maintenance olaparib or placebo until investigator-assessed disease progression or unacceptable toxicity.

The PFS and response were assessed by blinded independent central review using modified RECIST v1.1.

Of 92 patients in olaparib arm, 28 patients (30%) were aged ≥65, versus 13 of 62 patients (21%) in placebo arm.

Fewer older patients had ECOG performance status 0: of those ≥65 years 64% in olaparib arm versus 46% in placebo arm, while among those <65 years 73% versus 65%, respectively.

Median time from diagnosis to randomisation was shorter in patients ≥65 years 6.1 months versus 6.8 months and in those <65 years 7.3 months versus 7.1 months. All patients aged ≥65 were Caucasian (<65 years 84% versus 94%).

There was no difference in median baseline EORTC QLQ-C30 physical functioning score between age groups (≥65 years 87 versus 80; <65 years 87 versus 87; scale 0-100, higher score represents higher functioning).

At the data cut-off of 15 January 2019, 3 of 28 patients (11%) aged ≥65 years versus 7 of 64 patients (11%) aged <65 years had received olaparib for at least 2 years.

At 1 year, 21% of patients in olaparib arm versus 41% of patients in placebo arm aged ≥65 years were progression-free (<65 years: 39% versus 9%), and at 2 years, 21% of patients in olaparib arm versus 0% of patients in placebo arm remained progression-free (<65 years: 23% versus 9%). However, the study team commented that between-group comparisons may be impacted by small subgroups.

In total 4 of 28 patients (14%) aged ≥65 years had a partial response (PR; n=3) or complete response (CR; n=1) to maintenance olaparib versus 3 of 13 patients (23%, all PR) in the placebo arm (<65 years: 14 of 64 patients [22%, 1 CR] versus 3 of 49  patients [6%, all PR]).

Among responders aged ≥65 years, duration of first-line chemotherapy was 3.7-5.6 months and baseline characteristics were consistent with those of younger responders; the complete responder aged ≥65 years had metastatic lung disease and had received 5.6 months of first-line chemotherapy.

At the data cut-off, response duration among older patients was 10.2-32.2 months, and 3 of 4 were ongoing.

In total, 43% of patients treated with olaparib and aged ≥65 years experienced a grade ≥3 adverse event versus 33% of patients in placebo arm (<65 years: 38% vs 21%). Adverse-event and health-related quality of life profiles were consistent between the two age groups.

Overall patient’s age did not impact efficacy of maintenance olaparib, but subgroups were small. In the overall population, no baseline characteristics were predictive of olaparib efficacy in patients aged ≥65 years.

The study was funded by AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Reference

Abstract S-O3 – Kindler H, Hammel P, Reni M, et al. Maintenance olaparib in patients aged ≥65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO Trial. ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His House

A young boy in England got quite the surprise when he was handed a check for a job well done! The boy’s mom, Laura-Nicole, shared...

SABCS 2021: New Research and Updates in Breast Cancer Treatment and Side Effects

The 2021 San Antonio Breast Cancer Symposium (SABCS) was held from December 7 to 10 in San Antonio, Texas, and online. In this podcast,...

Cancer Research UK publishes gender and ethnicity pay gap reports

As part of Cancer Research UK’s ongoing commitment to improving the diversity of the organisation, the charity has today published its gender pay gap...

Can mRNA Vaccines Help Treat Cancer?

January 20, 2022, by NCI Staff A technician working on mRNA vaccine production. Credit: Image used with permission from BioNTech The coronavirus pandemic has thrown a spotlight...

A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma

COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival (PFS) in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in...

Wawa Employee Saves Life Of Customer Who Stopped Breathing After A Seizure

When 19-year-old John Wallop arrived for his 16-hour shift behind the deli counter at Wawa in Millville, New Jersey, he thought it would just...